These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36102396)

  • 1. Compounded medications for cardiovascular use in neonatology: an integrative review.
    Greenhalgh LL; Passos MMBD; Agrizzi AL; Monteiro MSSB
    Rev Paul Pediatr; 2022; 41():e2021167. PubMed ID: 36102396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical appraisal of commercially available suspending vehicles for extemporaneous compounding of cardiovascular medicines: physical and chemical stability mini review.
    Thrimawithana TR; D'Amore S; Dib Y; Fadavi Firooz N; Fakhouri W; Saeed A; Allahham A
    Pharm Dev Technol; 2019 Jun; 24(5):529-538. PubMed ID: 30238838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Extemporaneous Prescriptions Prescribed by Dermatovenerologists in Latvia and Comparison with Standardized Compounded Preparation Monographs of Germany and USA.
    Kiseļova O; Mauriņa B; Šidlovska V
    Medicina (Kaunas); 2020 Jan; 56(1):. PubMed ID: 31936697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective survey of compounded medications for children in Japan.
    Saito J; Akabane M; Ishikawa Y; Iwahashi K; Nakamura H; Yamatani A
    Eur J Pharm Biopharm; 2020 Oct; 155():122-127. PubMed ID: 32853693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of an alternative extemporaneous captopril fast-dispersing tablet formulation versus an extemporaneous oral liquid formulation.
    Pabari RM; McDermott C; Barlow J; Ramtoola Z
    Clin Ther; 2012 Nov; 34(11):2221-9. PubMed ID: 23149007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to age-appropriate essential medicines: a retrospective survey of compounding of medicines for children in hospitals in Nigeria and implications for policy development.
    Orubu ES; Okwelogu C; Opanuga O; Nunn T; Tuleu C
    Health Policy Plan; 2017 Mar; 32(2):225-235. PubMed ID: 28207051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4.
    Polonini H; da Silva SL; Brandão MAF; Bauters T; De Moerloose B; Ferreira AO
    Int J Pharm Compd; 2018; 22(6):516-526. PubMed ID: 30384353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extemporaneous compounding in a sample of New Zealand hospitals: a retrospective survey.
    Kairuz T; Chhim S; Hasan F; Kumar K; Lal A; Patel R; Singh R; Dogra M; Garg S
    N Z Med J; 2007 Mar; 120(1251):U2466. PubMed ID: 17384694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies.
    AlKhatib HS; Jalouqa S; Maraqa N; Ratka A; Elayeh E; Al Muhaissen S
    BMC Health Serv Res; 2019 Nov; 19(1):816. PubMed ID: 31703672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extemporaneous drug formulations.
    Nahata MC; Allen LV
    Clin Ther; 2008 Nov; 30(11):2112-9. PubMed ID: 19108799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
    Brion F; Nunn AJ; Rieutord A
    Acta Paediatr; 2003 Apr; 92(4):486-90. PubMed ID: 12801118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs.
    Lam MS
    Pharmacotherapy; 2011 Feb; 31(2):164-92. PubMed ID: 21275495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Most Frequently Prescribed Extemporaneously Compounded Veterinary Medications at a Large Independent Community Pharmacy.
    Karara AH; Hines R; Demir Z; Nnorom B; Horsey R; Twigg G
    Int J Pharm Compd; 2016; 20(6):461-467. PubMed ID: 28339384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Extemporaneously Compounded Nasal Preparations Prescribed by Latvian Otorhinolaryngologists and General Practitioners and Comparison with German Formulations.
    Kiselova O; Maurina B; Sidlovska V
    Int J Pharm Compd; 2020; 24(6):491-500. PubMed ID: 33217739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compounded medication for patients with rare diseases.
    Dooms M; Carvalho M
    Orphanet J Rare Dis; 2018 Jan; 13(1):1. PubMed ID: 29301541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence, Scope and Quality of Extemporaneous Medications in Selected Healthcare Facilities and Implications for Pharmacy Practice.
    Allotey-Babington GL; Akwo Kretchy I; Atiapa Asiedu E; Kelly Amuakwa M; Akwele Seaneke O; Ankrah D; Kwadwo Somuah A; Dei Owusu-Nyamekye A; Owusu-Ansah S; Kwame Effah P; Debrah J; Acheampomaa Nai E; Owusu E; Lamptey W; Gyekye IJA; Nettey H
    Innov Pharm; 2024; 15(1):. PubMed ID: 38779112
    [No Abstract]   [Full Text] [Related]  

  • 17. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products.
    Glass BD; Haywood A
    J Pharm Pharm Sci; 2006; 9(3):398-426. PubMed ID: 17207422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safe, swallowable and palatable paediatric mini-tablet formulations for a WHO model list of essential medicines for children compound - A promising starting point for future PUMA applications.
    Freerks L; Sommerfeldt J; Löper PC; Klein S
    Eur J Pharm Biopharm; 2020 Nov; 156():11-19. PubMed ID: 32871197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EVALUATION OF CASES WITH THE USAGE OF COMMERCIALLY AVAILABLE TABLETS IN THE PEDIATRIC FORMULA.
    Kuriata E; Sawicki W
    Acta Pol Pharm; 2015; 72(3):551-8. PubMed ID: 26642663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.